Administration of this drug in dogs results in progressive hypocoagulability as determined by coagulation assays, characterized by prolonged prothrombin and activated partial thromboplastin time.
Although activated clotting time and clot rates may become prolonged, platelet function parameters are usually unaffected.
Recommended dose rate is 25 - 175 U/kg given subcutaneously every 12 hours.
- Jessen LR et al (2008) In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time. Vet Clin Pathol 37(4):363-372
- Brainard BM et al (2012) Viscoelastic pharmacodynamics after dalteparin administration to healthy dogs. Am J Vet Res 73(10):1577-1582
- Scott KC et al (2009) Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis. J Vet Emerg Crit Care (San Antonio) 19(1):74-80
- Grebe S et al (2000) Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs. Berl Munch Tierarztl Wochenschr 113(3):103-107